Lilly

In conjunction with Lilly’s recent restructuring initiative, the company has named the leaders of its Development Center of Excellence (CoE) and its five business units: oncology, diabetes, established markets, emerging markets, and Elanco animal health.

Tim Garnett, M.D., and Tom Verhoeven, Ph.D., will lead the CoE within Lilly’s Research Laboratories. Dr. Garnett will have responsibility for medical, regulatory, global product safety, translational medicine and global health outcomes. Dr. Verhoeven will have responsibility for the clinical development organization, product R&D, toxicology/ADME and project management.

John H. Johnson will lead the oncology business unit. He currently serves as chief executive officer of ImClone Systems, which Lilly acquired last year. Enrique A. Conterno will lead the diabetes business unit. He currently serves as president of Lilly USA. Bryce D. Carmine will lead the established markets business unit. He currently serves as Lilly’s executive vice president of global marketing and sales. Jacques Tapiero, Lilly’s president of the intercontinental region, will lead the emerging markets business unit. Jeffrey N. Simmons will lead Elanco, the animal health business unit, where he currently serves as president. All appointments will become effective on November 1, 2009.

“These are proven leaders who bring a wealth of experience and knowledge to their respective roles,” said John C. Lechleiter, Ph.D., Lilly’s chairman, president and chief executive officer. “Each has demonstrated strong leadership and an ability to get results throughout their business careers. Moving forward, these individuals will play a critical role in the success of Lilly’s new operating model.”

Dr. Lechleiter outlined the details of the CoE, along with the criteria used to establish Lilly’s new business units. The CoE, which has more than 60 molecules in clinical development, will be tasked with streamlining the development of pipeline molecules.

In Oncology, Lilly plans to build its presence, aided by the acquisition of ImClone. Currently, one-third of the company’s pipeline consists of molecules to treat various forms of cancer.

Diabetes: Lilly has a dedicated portfolio of commercial products as well as pipeline opportunities. The company is also one of only a few global insulin suppliers.

Lilly’s other therapeutic areas, including neuroscience, osteoporosis/bone and cardiovascular, are included in the established markets business unit. This unit will have geographic responsibility for these therapeutic areas in the U.S., Japan, EU, Canada, and Australia/New Zealand. The unit will also host Lilly’s global marketing organization.

The Emerging Markets unit will include China, Russia, Brazil, Mexico, South Korea and Turkey. The company plans to increase its presence in these countries and others where strong growth rates for pharmaceuticals are projected over the next decade.

The company remains committed to the Elanco Animal Health unit, which is projected to have double-digit earnings growth during the next five years, bolstered by several recent acquisitions and the launch of its companion animal business.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference